Condition: Metastatic Solid Tumor · Recurrent Solid Tumor · Advanced Solid Tumor · Sponsor: Eli Lilly and Company
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
This description comes directly from the study's public registry record.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Recruiting |
| University of California, San Diego (UCSD) - Moores Cancer Center | La Jolla, California, United States | Not Yet Recruiting |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles, California, United States | Recruiting |
| Sarah Cannon Research Institute at HealthOne | Denver, Colorado, United States | Recruiting |
| Florida Cancer Specialists and Research Institute | St. Petersburg, Florida, United States | Completed |
| University of Chicago Hospital | Chicago, Illinois, United States | Recruiting |
| IU Simon Cancer Center | Indianapolis, Indiana, United States | Not Yet Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| START Midwest Cancer and Hematology Centers of W Michigan | Grand Rapids, Michigan, United States | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Recruiting |
| NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute) | New York, New York, United States | Not Yet Recruiting |
| Icahn School of Medicine at Mount Sinai | New York, New York, United States | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06465069